274. Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis

P2534
Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis
Barbara Hampel1, Olaf Schoeman2, Peter Reinmütz1, Paul Jones4, Robert Wilson3.
1Global Clinical Development Antiinfectives, Bayer Schering Pharma AG, Berlin, Germany; 2Global HEOR, Bayer Schering Pharma AG, Wuppertal, Germany; 3Division of Clinical Science, St George’s, University of London, London, United Kingdom; 4Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom

Introduction: Potentially pathogenic microorganisms (PPMs) frequently colonize lungs of bronchiectatic patients, often leading to pulmonary exacerbations. This phase II, randomized, double-blind study assessed the safety and efficacy of ciprofloxacin dry powder for inhalation (DPI) – a formulation (PulmoSphere™) using the T-326 inhaler – over 28 days in patients with sputum culture positive for predefined PPMs.

Objective: To test the effect of ciprofloxacin DPI on bacterial load and health status in non-cystic fibrosis bronchiectasis (non-CF BE) patients.

Methods: 124 adult, non-CF BE patients (mean baseline characteristics: age 63, 34% male, FEV1 56% of predicted) received 32.5mg ciprofloxacin (50 mg ciprofloxacin DPI) or matching placebo twice daily for 28 days with a 56-day follow-up. In addition to the primary endpoint (reduction in total bacterial load in sputum at end of treatment [EOT]), patient-reported health status was assessed with the St George’s Respiratory Questionnaire (SGRQ).

Results: Ciprofloxacin DPI reduced bacterial load at EOT (–3.6 vs –0.3 logs, \( p < 0.001 \)). The difference in mean SGRQ total score between active and placebo was –3.6 (\( p=0.059 \), 95% confidence interval –7.3 to 0.1), close to a clinically relevant (–4) improvement. The trend lasted for 4 weeks after EOT (difference –3.0) but was not maintained at 8 weeks after EOT (difference –0.83). SGRQ domain scores, responder and per-protocol analyses confirmed the trend.

Conclusions: Ciprofloxacin DPI clearly trended towards improving patient-reported health status in non-CF BE measured with the SGRQ, which lasted for 4 weeks after treatment finished. Further study is required to confirm the results.

P2535
Pseudomonas aerugenosa sensitivity changes to antibiotics under the influence of dissolved ozone
Alla Plotnikova1, Igor Belyanin2, Lubov Selina2, Evgenii Shmelev2.
1Microbiology, Central TB Research Institut, Moskow, Russian Federation; 2Microbiology, The Medical Center of the Help to Invalids without, Moskow, Russian Federation; 3Microbiology, Central TB Research Institut, Moskow, Russian Federation

Aim: To study the sensitivity changes of clinical strains of organisms producing beta-lactamases to antibiotics under the influence of dissolved ozone (pO3). We studied 20 Pseudomonas aerugenosa strains resistant to antibiotics of penicillin line. A suspension was prepared from the culture of each strain (1-2 × 10^8/ml) and treated with dissolved ozone (pO3 2mcg/ml) during 5-10-15 min. Then, the stains treated with pO3 were cultured on Muller-Hinton agar containing a strain resistant antibiotic. The same strain that had not been treated with pO3 was also cultured on the same agar containing the same antibiotic (control). In a day after incubation by 370C we recorded the result of the diameter zone of growth inhibition round the antibiotic disc.

Results: The zone of growth inhibition round the antibiotic disc increased from 0 to 2.1 ± 3.5 mm in all cases of Pseudomonas aerugenosa strain culture. There were no growth changes in control cultures.

Conclusion: The treatment of resistant strains of Pseudomonas aerugenosa with “therapeutic concentration” of dissolved ozone results in antibiotic sensitivity restoration.

P2536
Influence of antibiotic resistance of pseudomonas aeruginosa on presenting features of community-acquired lower respiratory tract infections
Pavlina Nikolova1, Yavor Ivanov1, Plamen Pavlov1, Tsania Popova1, Elena Bortissova1, Petkana Hristova1.
1Pulmonary Clinic, Medical University, Pleven, Bulgaria; 2Clinic of Internal Diseases, Medical University, Pleven, Bulgaria; 3Department of Social and Preventive Medicine, Medical University, Pleven, Bulgaria

Aim: To evaluate the influence of resistant isolates of Pseudomonas aeruginosa on presenting features for patients with community-acquired lower respiratory tract infections (LRTrs).

Methods: 95 hospitalized patients (67 men, 28 women, average age 66,7±10,9y)

463s

Abstract printing supported by Chiesi. Visit Chiesi at Stand D.30
with community acquired pneumonia (CAP), bronchiectasis and exacerbations of chronic obstructive pulmonary disease (COPD) and Pseudomonas aeruginosa isolates were studied during a 5-year period. They were divided into two groups: with susceptible isolates (n=67, 73.7%), S group resistant to antibiotic testing, (n=25, 26.3%, R group) and compared by sex, age, diagnosis, comitant diseases, treatment, length of stay, outcome.

**Results:** 14% of the patients had CAP, 46.3% - bronchiectasis and 40% - COPD. Most of them had concomitant diseases - ischaemic heart disease: S/R - 62.4%/62% resp., diabetes - S/R -11%/12% resp. We found differences in: the change of antibiotic treatment according to microbiological results (85%/36%/S p =0.005); length of hospital stay >15 days - 3%/12% resp. p<0.05. Complications of the essential disease were more in the R group (2%/4%). The outcome was similar in both groups.

**Conclusions:** The clinical features found in patients with resistant isolates of P. aeruginosa compared to susceptible ones were: more complications of the main disease, more frequent change of antibiotics during the course of treatment according to the microbiological results and longer length of stay.

### P2537

**Nebulized antibiotics in patients with non-cystic fibrosis bronchiectasis ans chronic pseudomonas aeruginosa infection**

Jose R. Donado-Ulha1, Carolina Jimenez-Navarre2, Marialyng E. Fuentes-Salazar1, Jose M. Ruiz-Guardian3, Miguel A. Racaccea4, Vicente Valeri-Busto1, Eva Prats-Graciá1, Antonio Zapatero-Gaviria1.

1Respiratory Medicine, Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain; 2Internal Medicine, Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain; 3Intensive Care, Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain

**Methods:** Retrospective review of patients with bronchiectasis with Pseudomonas aeruginosa (PA) isolated from sputum at least twice during the year prior to nebulized antibiotic (NA) onset and a minimum 6-month follow-up.

**Results:** 17 patients included (9 men), median age 69.7 yrs, average follow-up 753 days (183-1824). Nine patients received more than 1 NA during follow-up (31 NA courses in total): 16 colistin, 14 tobramycin, 1 gentamicin. Average treatment duration: 492.5 days (100-971). Subjective improvement was referred by 12 patients (70.5%). Eradication of PA was achieved in 7 (41.2%), but 1 relapse occurred. 8 patients presented side effects at any time during NA (47%), mainly bronchospasm. Table 1 shows a reduction in mean number of admissions/year and mean days of admission/year for all patients. A statistically significant reduction is observed when PA was eradicated.

### Table 1

<table>
<thead>
<tr>
<th>Period</th>
<th>Aquisitions/year</th>
<th>Days in hospital/year</th>
<th>Difference</th>
<th>p&lt;***</th>
</tr>
</thead>
<tbody>
<tr>
<td>NA</td>
<td>2.24 ± 1.17</td>
<td>31.35 ± 39.1</td>
<td>1.5 ± 1.53</td>
<td>0.73 ± 0.97</td>
</tr>
<tr>
<td>NA</td>
<td>1.07 ± 1.27</td>
<td>16.58 ± 17.53</td>
<td>1.07 ± 1.27</td>
<td>1.9 ± 3.3</td>
</tr>
<tr>
<td>NA</td>
<td>1.07 ± 1.27</td>
<td>16.58 ± 17.53</td>
<td>1.07 ± 1.27</td>
<td>1.9 ± 3.3</td>
</tr>
</tbody>
</table>

**Conclusion:** Mannose binding lectin deficiency is associated with disease severity in patients with non-cystic fibrosis bronchiectasis.

### P2538

**Mannose binding lectin deficiency is associated with disease severity in patients with non-cystic fibrosis bronchiectasis**

James D. Chalmers1, David Kilpatrick2, Brian McHugh3, Pallavi Mandal1, Maeve Smith3, Cathy Doherty4, John Govan4, Adam T. Hill3.

1MRC Centre for Inflammation Research, Queen’s Medical Research Institute, Edinburgh, United Kingdom; 2Scottish National Blood Transfusion Service, NHS Lothian, Edinburgh, United Kingdom; 3Department of Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom; 4Cystic Fibrosis Laboratory, University of Edinburgh, Edinburgh, United Kingdom

**Background:** Mannose binding lectin (MBL) is a serum protein involved in phagocytic clearance of bacteria, viruses and apoptotic cells. Deficiency of mannose binding lectin is associated with disease severity in cystic fibrosis bronchiectasis but has not been studied in adult non-cystic fibrosis bronchiectasis. MBL deficiency patients with non-cystic fibrosis bronchiectasis (confirmed by HCR) and matched controls were recruited. MBL serum levels were measured by ELISA. MBL deficiency was defined as a serum level <0.5g/l. Quantitative microscopy was performed on spontaneous sputum samples to determine bacterial load expressed as Log10 colony forming units/ml (cfu/ml).

**Results:** MBL deficiency was not more frequent in bronchiectasis patients than controls (27.2% vs. 29.6%, p=0.4). MBL deficient patients had more severe disease as defined by lung function (39.6% vs. 19.3%, p<0.001). They suffered more frequent exacerbations (mean 2.8/year vs. 1.4/year, p<0.0001) and were more frequently hospitalised for severe exacerbations (31.3% hospitalised vs. 18.1% hospitalised during follow-up). MBL deficient patients more frequently met the criteria for chronic colonisation (70.3% vs. 51.5%, p=0.002). Among those colonised, MBL deficient patients, (n=70, 73.7%, S group) had more severe disease (the concentration of azithromycin was 8ug/ml, the formation of the biofilm was blocked by MBL 256 ug/ml, but inhibited the biofilm formation when the concentrations were less than 8ug/ml. When the PAO1 was cultured in LB, azithromycin could induce the biofilm formation at the sub-MIC concentrations. Ciprofloxacin and cefazolin could inhibit the biofilm formation at the sub-MIC concentration. Amikacin could induce biofilm formation at the concentration of 0.125 and 0.25ug/ml cultured in MHB and LB respectively. All the results above had statistical difference compared with the blank. The Fucizone C-30 was added in the static biofilm model with the azithromycin concentration 8ug/ml and 4ug/ml, the results had no statistical difference. (3) Silver staining results: when the concentration of azithromycin was 8ug/ml, the formation of the biofilm was blocked by MBL 256 ug/ml, but inhibited the biofilm formation when the concentrations were less than 8ug/ml. When the PAO1 was cultured in LB, azithromycin could induce the biofilm formation at the sub-MIC concentrations. Ciprofloxacin and cefazolin could inhibit the biofilm formation; amikacin could induce the biofilm formation at the concentration of 0.125ug/ml and 0.25ug/ml.

**Objective:** To study the effects of the subinhibitory concentrations of four antibiotics on the biofilm formation of Pseudomonas aeruginosa.

**Methods:** 2 types of culture media of 1-broth (LB) and mueller-hinton broth (2 Schae) of immunity and infection, University of Birmingham, Birmingham, United Kingdom

**Background:** Pseudomonas aeruginosa (PA) colonisation is commonly encountered and problematic in patients with nonCF bronchiectasis. Inhibitory factors in the serum of patients with CF and chronic PA infection which impair phagocytosis of PA have previously been identified with IgG2 proposed to act as a blocking antibody. We have investigated this concept further in patients with non CF bronchiectasis.

**Methods:** Stable state serum and sputum collected from 11 patients with non CF bronchiectasis colonised with PA. 33 morphological strains of PA identified from this group. Control serum was obtained from healthy individuals for comparison. Stationary phase bacterial cultures were prepared and 10μL inoculum added to 90μL of healthy control and patient serum and incubated at 37°C for 3 time intervals (45,90,180 mins) the serum/inoculum mixture underwent serial dilution and a miles/mira plate prepared for each strain at every time point at 4 dilutions. This was incubated overnight at 37°C and colonies analysed to observe the serum killing trend.

**Results:** Serum from 2 patients was demonstrated to have blocking activity against 4 strains of PA isolated from these patients.
Conclusions: The concept of blocking activity in the serum of patients with non-CF bronchiectasis may provide some explanation for the mechanism of establishment of PA colonisation in the airways of some patients and requires further investigation.

P2541
Sputum neutrophils are related to functional status in non-cystic fibrosis bronchiectasis in subjects in airway colonization

Federico L. Dente, Laura Malagrinò, Francesco Costo, Lorena Melovini, Antonella Di Franco, Maria Laura Bartoli, Cristina Ferretti, Mariella De Santis, Elena Bacci, Pier Luigi Paggiano. Cardio-Thoracic Department, Respiratory Pathophysiology Section, Pisa, Italy

In 42 subjects with bronchiectasis (13 male, mean age 62.4 ± 9.3 years, 32 non-smokers, 9 ex and 1 current smoker), functional status and airway inflammation were measured. All subjects showed diffuse bronchiectasis (equally divided in 3 subjects), pulmonary consolidations in 30, and peri-bronchiectasis eudesitations in 29 subjects. Bronchiectasis was idiopathic in 22, post-infectious in 15, post-CTB in 5 patients. Bacterial airway colonization was demonstrated in 20 out of 32 subjects collecting sputum (8 Pseudomonas, 2 NTMB, 5 Proteus/E. coli, 4 Stafilococcus, 1 Hemophilus infl., 1 Streptococcus). Obstructive syndrome was found in 28 subjects, restrictive syndrome in 2, and normal spirometry in 12. Hyperlinal-sine-induced sputum was collected in 36 subjects: 29 showed increased neutrophil% (median 79.9%), while 5 subjects showed increased eosinophil%. All except 5 out of 34 subjects showed normal values in exhaled nitric oxide (17.5 ± 16.1 ppb). Significant correlations were found between sputum neutrophil% and FEV1% pred, FEV1/VC% pred, and RV% pred. These significant correlations were maintained considering subjects with airway colonisation, but not in subjects without it.

Correlation between Sputum Neutrophil % and functional findings (r, p)

<table>
<thead>
<tr>
<th>FEV1 % pred</th>
<th>FEV1/VC % pred</th>
<th>RV % pred</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td>-0.64, &lt;0.0001</td>
<td>-0.54, 0.0006</td>
</tr>
<tr>
<td>Airway colonization</td>
<td>-0.66, 0.001</td>
<td>-0.48, 0.05</td>
</tr>
<tr>
<td>No airway colonization</td>
<td>-0.40, n.s.</td>
<td>-0.39, n.s.</td>
</tr>
</tbody>
</table>

In conclusion, significant relationships between sputum neutrophils, and functional findings were found in patients with bronchiectasis and bacterial airway colonization, suggesting that the last one has a role in pulmonary function impairment.

P2542
Survey of microbiology, pseudomonas eradication and antimicrobial prophylaxis in adult patients with non-cystic fibrosis bronchiectasis

Rahul Bhatnagar, Nicholas Withers. Department of Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter, United Kingdom

Introduction: Recent guidelines on non-CF bronchiectasis advocate the use of prophylactic antibiotics in frequent exacerbators, and eradication of Pseudomonas Aeruginosa (PA) on first isolation in sputum. We examined the sputum microbiology and antimicrobial treatment in a cross-section of patients seen within our respiratory service.

Methods: Data was collected on all patients seen for routine follow up of non-CF bronchiectasis for 4 months, We analysed PA status; Prior attempts at eradication of PA; The use of prophylactic antibiotics; and sputum microbiology for the preceding 5 years.

Results: 210 patients were included. The commonest bacterial isolate over the 5 years, other than PA (36%), was Haemophilus influenzae (27%). 48 had positive cultures for PA in the previous 12 months. 40 patients grew PA for more than one year’s duration. Eradication had been attempted in 62% of the patients who grew PA. Regimens included Ciprofloxacin (28%), nebulated colomycin (23%), and a combination of both (26%). 78 (37%) patients were on prophylactic antibiotics, with thrice weekly Azithromycin being used in 61 patients. 47% had been positive for PA at some point. Data for annual exacerbation rates was not available.

Conclusions: PA was cultured in just over a third of patients, with approximately two thirds of these having undergone some attempt at PA eradication using methods in line with recently published guidelines. Only 38% of those remain clear of PA for more than 1 year afterwards. Approximately 50% of patients on prophylactic antibiotics had no recent isolation of PA, although exacerbation rate data was not included in this survey.

P2543
Inhaled antibiotic treatment. Tolerance, compliance and quality of life of Antonio Alvarez1, Laura Ruano1, Montserrat Vendrell2, Rosa Giron2, MP Pilar Ausin2, Miguel Angel Martinez2, Marina Blanco2, David de la Rosa2, David Blanquer1, Iñes Herrozo1, Javier de Gracia1.1 Pneumology Department, Hospital de Reina, Reina, Valencia, Spain; 2Pneumology Department, Hospital Universitari Dr Josep Trueta, Girona, Spain; 3Pneumology Department, Hospital Universitario de la Princesa, Madrid, Spain; 4Pneumology Department, Hospital Del Mar, Barcelona, Spain; 5Pneumology Department, Hospital del Rosellon, Barcelona, Spain; 6Pneumology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain

Methods: Adults attending a bronchiectasis clinic from Dec 2010-Jan 2011 were screened. Spirometry was performed & GOLD criteria for COPD were used to categorise AO. Functional ability was assessed using the MRC dyspnoea (MRCD) scale. The Hospital Anxiety and Depression Scale (HADS) was used to screen for anxiety and depression. A score of ≥ 8 in either sub-scale (HADS-A, HADS-D) was deemed clinically significant.

Results: N=52 (34F, 18M). Mean age: 61 (SD 13.4). 30 patients (57.7%) had evidence of AO. 6 patients (20%) had mild AO; 11 patients (37%) had moderate AO; 11 patients (37%) had severe AO and 2 patients (6%) had very severe AO. 27 patients (48%) had a HMSCD score of ≥ 3; 30 patients (42.3%) had a HADS-A score of ≥ 8. 19 patients (28.8%) had both HADS-A and D scores of ≥ 8. Chi-square analysis showed significant association of clinically significant HADS-A (p<0.01) and HADS-D (p=0.013) scores with a HMSCD score of ≥ 3. There was no significant correlation between FeV1 (% predicted) and HADS-A (p=0.63) or D (p=0.98) scores.

Discussion: Many patients had severe or very severe airflow obstruction. 50% of

P2544
Azithromycin, a novel maintenance therapy in patients with chronic non-CF supplicative lung disease

Simon Twite, Paul Stockton, Sanjeev Agarwal. Respiratory Medicine, St. Helens and Knowsley NHS Trust, Liverpool, Merseyside, United Kingdom

Patients with bronchiectasis experience lower respiratory tract infections with decline in quality of life. The British Thoracic Society statement indicates that Macrolides may have disease-modifying activity. A definite recommendation for their use is not made in non-CF bronchiectasis. We present experience of Azithromycin in non-CF bronchiectasis as well as other respiratory diseases at a large district general teaching hospital.

137 patients were identified on maintenance Azithromycin therapy during a 12 month period. 66% received Azithromycin 250mg daily. Azithromycin provided a significant improvement in the mean time between exacerbations/hospital infectious episodes, in patients with non-CF bronchiectasis as well as other lung conditions. The mean time to exacerbation was 64 days, without Azithromycin (range 30-360 days) versus 304.5 days, with Azithromycin (range 14-582 days). 48 patients required rescue antibiotics. Where Azithromycin was electively withdrawn, the patients were clinically worsened. This strategy is therefore not recommended. Treatment failure due to side effects only occurred in those patients on a 500mg three times weekly regime. Discussion in the literature raises concerns with atypical mycobacteria, potential for increased colonisation rates and drug resistance. No such concerns were seen in this series. In this series, Azithromycin provided clinical improvement in patients with other non-CF lung disease processes but further studies are needed in this population.

The recommended regime from this study, in those patients with non-CF bronchiectasis is Azithromycin 250mg PO daily.

P2545
Airflow obstruction, functional disability and psychological dysfunction in bronchiectasis

Graham Miller, Helmy Haja Mydin, Anthony De Soyza. Cardiothoracic Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Introduction: The impact of airflow obstruction, functional disability and psychological dysfunction has previously been described in COPD but not in bronchiectasis. We hypothesised that anxiety and depression may be commoner in bronchiectasis patients with poor functional capacity or evidence of airflow obstruction (AO).

Methods: Adults attending a bronchiectasis clinic from Dec 2010-Jan 2011 were screened. Spirometry was performed & GOLD criteria for COPD were used to categorise AO. Functional ability was assessed using the MRC dyspnoea (MRCD) scale. The Hospital Anxiety and Depression Scale (HADS) was used to screen for anxiety and depression. A score of ≥ 8 in either sub-scale (HADS-A, HADS-D) was deemed clinically significant.

Results: N=52 (34F, 18M). Mean age: 61 (SD 13.4). 30 patients (57.7%) had evidence of AO. 6 patients (20%) had mild AO; 11 patients (37%) had moderate AO; 11 patients (37%) had severe AO and 2 patients (6%) had very severe AO. 27 patients (48%) had a HMSCD score of ≥ 3; 30 patients (42.3%) had a HADS-A score of ≥ 8. 19 patients (28.8%) had both HADS-A and D scores of ≥ 8. Chi-square analysis showed significant association of clinically significant HADS-A (p<0.01) and HADS-D (p=0.013) scores with a HMSCD score of ≥ 3. There was no significant correlation between FeV1 (% predicted) and HADS-A (p=0.63) or D (p=0.98) scores.

Discussion: Many patients had severe or very severe airflow obstruction. 50% of
P2546
Staphylococcus aureus sensitivity changes to antibiotics under the influence of dissolved ozone
Igor Beljarin, Lubov Selina, Evgeniy Shmelev, Alla Plotnikova. Microbiology, Central TB Research Institute, Moscow, Russian Federation

Aim: To study the sensitivity change of the clinical strains of staphylococcus aureus to antibiotics under the influence of dissolved ozone. (pO3).
Methods: We investigated 20 S.aureus strains from sputum culture resistant antibiotics. A suspension was prepared from a day portion of the agar culture of each strain (1-2 x 10^7/ml), which was treated with dissolved ozone (pO3 3mg/m^3) or with air (control) during 5-10-15 min. Then, the strains treated with pO3 were cultured on Mueller-Hilton agar containing strains resistant antibiotics and incubated at 370C. In a day of incubation we recorded the results of antibiotic resistance change according the diameter zone of the growth inhibition round the antibiotic disc.

Results: The growth inhibition zone increased from 3.8 to 27.2±2.1 mm in all cases of cultured S.aureus strains treated with pO3. And in cases with control strains the growth inhibition zone was not change.

Conclusion: Staphylococcus aureus sensitivity to antibiotics restores after dissolved ozone treatment.

P2547
Identification of four different metallo-beta-lactamases, IMP-1, IMP-7, IMP-19 and VIM-2, in Japanese general hospitals
Naohiro Shihata, Hiroyuki Ohyabashi. Department of Allergy and Respiratory Medicine, Tohon-Kousei Hospital, Mizunami, Japan

Background: Metallo-beta-lactamases (MBLs) are bacterial enzymes that hydrolyze carbapenems. MBL-producing gram-negative bacilli have been emerging worldwide. In this study different MBLs were identified in various lung diseases in the Japanese clinical hospitals.

Methods: From Jan. 2009 to Dec. 2010, 1618 GNB strains were submitted to the laboratory of 6 general hospitals in Aichi prefecture. Strains demonstrating a high level ceftazidime resistance (MIC, ≥128 mg/ml) were subjected to a screening test for MBL production by using disks containing an MBL inhibitor, sodium mercaptocetic acid (SMA). PCR and sequencing analyses were performed to confirm the types of MBLs and integrase using primers specific for each gene.

Results: Fifty-three strains (34 Pseudomonas aeruginosa, 11 P. putida and 8 Acinetobacter baumannii) were isolated from elderly patients in various wards. These strains were isolated from various respiratory specimens (sputum, pus). PCR analyses, 35 IMP-1 producers (26 P. aeruginosa and 9 P. putida), 8 IMP-7 producers (8 P. aeruginosa), 4 VIM-2 producers (4 P. putida) and 8 IMP-19 producers (8 A. baumannii) were found. Three IMP-1 and 2 VIM-2 producers were isolated in the same hospital. All MBL genes identified in this study were mediated by class 1 integron.

Discussion: In this study, four different MBLs were identified in 6 general hospitals. This may owe to excessive use of broad-spectrum β-lactamases, IMP-1, IMP-7, IMP-19 and VIM-2, and also to the spread of these genes through different hospitals.

P2548
Anxiety and depression in patients with bronchiectasis related to bacterial colonization
Gilda Fernandes1, Cristina Martin-Carbajo2, Rosa Girén2, Emma Vasquez1, Carolina Cunyeros1, Lourdes Ramos2, Consolación Rosado3, Julio Ancochea2.

The objective of this study was to assess anxiety and depression by using questionnaires completed by patients with bronchiectasis, who were monitored in a Monographic Clinic.

Patients and methods: We included patients diagnosed with non-cystic fibrosis bronchiectasis, monitored by means of Computed Axial Tomography. The patients were in a stable state and they filled in the Beck depression questionnaire and the state anxiety and trait anxiety Inventory after signing a statement of informed consent.

We collected the following variables: age, sex, and presence or absence of bacterial colonization that was considered by isolating the same type of bacteria in three consecutive sputum separated by a minimum interval of one month. Patients were classified into different degrees of depression and the various percentiles of anxiety. These results were compared to the presence or absence of bacterial colonization.

Results: 45 patients responded voluntarily to the questionnaires, 35 women, with a mean age of 66.46 (14.6) years. 16 were chronically colonized, with 12 cases of Pseudomonas aeruginosa. 42.5% of patients (30% mild depression, 12.5% moderate) had depression. 65% of patients reported in both the state anxiety and anxiety state. State anxiety and trait anxiety were associated with bacterial colonization (p=0.005 and p=0.013) and more specifically to the colonization by Pseudomonas aeruginosa (p=0.007 and p=0.029).

Conclusions: Patients with bronchiectasis showed a high percentage of anxiety, both state and trait, as well as depression, although most of this is mild. The chronically colonized patients have higher levels of anxiety in these two aspects.

P2549
Microbiological pattern in infective episodes of bronchiectasis Abdalla Khoury1, Hassan Ismaeil1, Hivin Hannan2, 1Department of Pulmonary Diseases, Aleppo University Hospital, Aleppo, Syrian Arab Republic; 2Department of Internal Medicine, Aleppo University Hospital, Aleppo, Syrian Arab Republic

Background: Infections usually cause inflammatory reaction and destruction of bronchial wall, this further leads to more disturbance in local defense and a vicious cycle of inflammation and bacterial colonization occurs.

Objectives: The purpose of this paper was to studying the microbiological pattern during infective episodes of Bronchiectasis and possible relation between the invasive Bacteria and lung functions.

Materials and methods: A retrospective analysis of 60 episodes in 50 patients. Forty five patients fulfilled our protocol criteria of reliable microbiological result and reproducible lung function tests. The patients were categorized into three stages of severity. Fibroptic bronchoscopy was performed just after specimen, BAL was sampled and the results of the bacterial growth were reported. A discriminatory cutoff point of 0.10000 CFU was used.

Results: H.influenza was the causative agent in 10 episodes (17%), 8 pneumococci in (14%) and Strep. pneumonia in (9%). Morecuta catarrhalis in 7 (12%) episodes. Lung function tests revealed an FEV1 with 50% of predicted value in 20 patients (stage 1), an FEV1 with 35-50% in 12 patients (stage 2) and an FEV1 with 35% in 8 patients (stage 3).

There was a correlation between deterioration of lung function and the bacteria isolated from patients with infective exacerbations of Bronchiectasis, in acute episodes Pseudomonas Aeruginosa and Enterobactericeae were the predominant bacteria in patients with FEV1 at 35% of predicted value.

Conclusions: There were no correlations between the isolated bacteria and the duration of symptoms, number of previous hospitalization, or radiological findings. In contrast there was a correlation between the deterioration of lung function and the isolated bacteria.

P2550
The role of viruses and other atypical bacteria in bronchiectasis' exacerbations
Evangelos Balis1, Eugenios Metaxas1, Despina Chrysoverygi2, Josip Paparazkaes3, Nikolaos Spanakis1, George Tatsis1, Athanasios Tsakris3, Pulmonary, Evangelismos General Hospital, Athens, Greece; 23rd Internal Medicine, Evangelismos General Hospital, Athens, Greece; 3Microbiology, Medical School of Kapodistrian University, Athens, Greece

Introduction: Exacerbations in patients with bronchiectasis, is thought to occur either because of change in the bacterial load of an existing bacteria or because of colonization with a new bacterial strain. Despite the existence of data for the role of viruses and atypical bacteria in patients with COPD, there is paucity of data about their role in bronchiectasis.

Aims and objectives: To study the effect of atypical bacteria and viruses in bronchiectasis exacerbations

Methods: An observational study was performed. For 12 months, 33 patients with bronchiectasis were followed up in 4 months intervals. They were submitted to bronchoscopy in an effort to determine baseline bacteria. Bronchoscopy was also performed during exacerbations. Real time polymerase chain reaction (PCR) was performed in bronchoalveolar lavage (BAL) samples for the detection of Chlamydia pneumoniae, Mycoplasma pneumoniae and Respiratory syncytiat virus (RSV). In addition, antibody titers against Influenza A, Influenza B, Adenovirus, C pneumoniae and M. pneumoniae were measured.

Results: In total 116 visits were performed (97 baseline and 19 exacerbations). After the first 30 PCR tests, because of cost restrictions, PCR was agreed to be performed only in cases of elevated IgG, seroconversion, or positive IgM titers. Totally 74 PCR tests were performed. RSV was isolated in 4 subjects during exacerbation periods and none during exacerbations. All PCR tests were negative for atypical bacteria. There was no detection of IgM antibodies against the aforementioned microorganisms.

Conclusions: Despite the small number of recorded exacerbations, atypical bacteria and viruses do not seem to have a role in exacerbations in patients with bronchiectasis.

466s

Abstract printing supported by G Chiesi Visit Chiesi at Stand D.30

Thematic Poster Session
Hall 2-27 - 12:50-14:40

MONDAY, SEPTEMBER 26TH 2011